Evidence-based guide to finasteride use in transplant recipients, people living with HIV, patients with liver disease, and other special populations. Covers drug interactions, dose adjustments, and monitoring.
Finasteride at ages 18-29: compare actual sexual-effect, mood and fertility studies, distinguish 1 mg from 5 mg evidence, and assess topical alternatives.
A clinical guide to monitoring flibanserin (Addyi) in premenopausal adults aged 30 to 49, covering liver function, blood pressure, alcohol screening, CNS depression risk, and CYP3A4 drug interactions.
A clinical review of flibanserin (Addyi) safety data for premenopausal women aged 30 to 49, covering side effects, drug interactions, alcohol warnings, and monitoring recommendations.
A clinician-grade guide to every major flibanserin (Addyi) drug interaction, including CYP3A4 inhibitors, alcohol, CNS depressants, hormonal contraceptives, and P-gp substrates, with FDA and PubMed citations.
A clinical review of flibanserin (Addyi) pipeline developments, new delivery systems under investigation, and the future of HSDD pharmacotherapy for premenopausal women.
Flibanserin is contraindicated in all degrees of hepatic impairment due to a 4.5-fold increase in drug exposure. Learn the pharmacokinetic data, FDA warnings, and clinical alternatives.
A clinical history of flibanserin (Addyi), from its origins as a failed antidepressant to its FDA approval for hypoactive sexual desire disorder in premenopausal women, including mechanism of action, key trials, and regulatory timeline.
Evidence-based monitoring schedule for flibanserin (Addyi), including baseline labs, liver function testing, blood pressure checks, and follow-up exam intervals.
A clinician-grade review of flibanserin off-label uses beyond FDA-approved HSDD in premenopausal women, with trial data, evidence grading, and safety considerations for each indication.
Clinical guide to flibanserin (Addyi) overdose management, including symptoms of excess dosing, pharmacologic mechanisms, emergency treatment protocols, and prevention strategies backed by FDA labeling and trial data.
A clinical breakdown of flibanserin (Addyi) patent status, regulatory exclusivity, generic approval pathway, and projected availability dates for generic versions.
Is flibanserin (Addyi) safe during pregnancy or breastfeeding? A clinician-grade review of FDA labeling, animal reproductive data, lactation pharmacokinetics, and practical guidance for HSDD management in the peripartum period.
A clinical review of flibanserin (Addyi) real-world evidence from registries, post-market surveillance, and observational studies, including mechanism of action and effectiveness outside clinical trials.
Evidence-based protocol for discontinuing GHK-Cu (copper tripeptide) injections or topical use, including taper schedules, monitoring, and what to expect after stopping.
Evidence-based review of GHK-Cu (copper tripeptide) drug-drug interactions, including copper chelators, NSAIDs, anticoagulants, and immunosuppressants. with PubMed citations.
No GHK-Cu dose has been established for liver disease. It covers FDA status, copper in liver disease and the limited human evidence.
Trace the full history of copper tripeptide GHK-Cu from its 1973 discovery in human plasma through decades of wound-healing research to its current use in compounding pharmacy and dermatology.
Reviews what is known about GHK-Cu absorption, distribution, metabolism and excretion, and where human pharmacokinetic data are missing.
Is copper tripeptide GHK-Cu safe during pregnancy or breastfeeding? A analysis of the preclinical data, copper biology, and clinical unknowns.
A review of human and real-world evidence for GHK-Cu: no registries or cohorts found, a few small randomized trials, and mostly laboratory data.
No kidney-adjusted GHK-Cu dose exists. See what FDA, small human trials and a CKD copper study say about copper peptide in kidney disease.
A clinician-grade review of copper tripeptide GHK-Cu safety signals, FDA regulatory actions, compounding pharmacy oversight, and adverse event data from published literature.
Find out whether Blue Cross Blue Shield of Massachusetts covers liraglutide (Saxenda) for weight loss, including prior authorization requirements, step therapy, copay estimates, and appeal options.
In separate placebo-controlled trials, tirzepatide produced -20.9% weight change at 72 weeks and naltrexone-bupropion -6.1% at 56 weeks.
GLP-1 receptor agonists may offer metabolic benefits before prediabetes is diagnosed. Learn what the clinical evidence says about early intervention with semaglutide, tirzepatide, and liraglutide for people with obesity or insulin resistance who have not yet crossed the prediabetic threshold.
Find out whether Aetna covers Ozempic for type 2 diabetes or weight loss, what prior authorization requires, step therapy rules, out-of-pocket costs, and how to appeal a denial.
Find out whether Affinity Health Plan covers Saxenda (liraglutide 3.0 mg) for weight management, what prior authorization requirements apply, and how to appeal a denial.
Find out if BCBS covers tirzepatide (Mounjaro) for type 2 diabetes and weight management, including prior authorization steps, step therapy rules, and appeal options.
BCBS plans typically cover Trulicity (dulaglutide) for type 2 diabetes, but formulary tier, prior authorization rules, and out-of-pocket cost vary by state and plan. Here is what to expect.
What is actually known about Blue Cross Blue Shield of Alabama's coverage of Ozempic (semaglutide): formulary placement, prior authorization, step therapy, cost ranges, and what you need to verify directly with your plan.
Find out whether Blue Cross Blue Shield of Arizona covers Saxenda (liraglutide 3.0 mg) for weight management, including prior authorization requirements, step therapy, cost details, and alternative options.
Find out whether Blue Cross Blue Shield of Arizona covers Trulicity (dulaglutide), what formulary tier it sits on, prior authorization rules, and how to reduce your out-of-pocket cost.
A clinical breakdown of BCBSIL coverage for liraglutide (Saxenda), including prior authorization criteria, step therapy requirements, expected copays, and alternatives if your claim is denied.
Find out whether Blue Cross Blue Shield of Michigan covers Saxenda (liraglutide 3.0 mg), what prior authorization criteria apply, expected copays, and how to appeal a denial.
Find out whether Blue Cross Blue Shield of Michigan covers Wegovy (semaglutide 2.4 mg) for weight loss, including prior authorization criteria, out-of-pocket costs, step therapy requirements, and appeal options.
Find out whether Blue Cross Blue Shield of Michigan covers Trulicity (dulaglutide), what formulary tier it falls on, prior authorization requirements, and how to reduce your out-of-pocket cost.
Find out whether BCBS of Minnesota covers Saxenda (liraglutide 3 mg) for weight loss, including prior authorization criteria, copay estimates, step therapy rules, and appeal options.
Standard GLP-1 titration runs 16-20 weeks in fixed steps to limit GI side effects; survodutide isn't FDA-approved, so no official schedule exists yet.
Compounded liraglutide is not FDA approved and has no timeline of its own. The Saxenda label reaches 3 mg daily by week 5 and checks weight at 16 weeks.
Evidence-based dietary strategies for patients on semaglutide, tirzepatide, and other GLP-1 receptor agonists, including protein targets, meal timing, hydration, and micronutrient considerations.
A clinical comparison of online weight loss injection prices, covering branded GLP-1s, compounded semaglutide, tirzepatide, and telehealth platform costs in 2026.
A clinical guide to GLP-1 (glucagon-like peptide-1), how GLP-1 receptor agonist medications produce weight loss, FDA-approved options, trial data, eligibility, and what to expect on treatment.
A fitness coach designs individualized training, nutrition, and recovery programs. Learn how high performers use coaching alongside clinical optimization to maximize physical output and longevity.
Calibrate pairs GLP-1 medications with metabolic health coaching. Here is what the clinical evidence and employer outcomes data say about weight loss, healthcare savings, and workforce productivity.
Diabetes and high cholesterol frequently coexist, compounding cardiovascular risk. Learn how insulin resistance drives dyslipidemia, which labs to monitor, and evidence-based treatments that address both conditions.
Evidence-based daily protein requirements by age, sex, activity level, and health goal. Includes RDA guidelines, athletic targets, and clinical trial data on optimal intake.
A clinical guide to choosing a qualified nutrition coach, including credentials to verify, red flags to avoid, and how coaching improves outcomes for weight management, metabolic health, and hormone therapy.
A step-by-step guide for healthcare providers, pharmacies, and wellness brands seeking telehealth clinic partnerships, covering compliance, technology integration, credentialing, and revenue models.
Step-by-step guide to measuring waist, hip, neck, and limb circumferences accurately at home, with clinical thresholds, equipment tips, and interpretation guidance.
When to remove Tasso+, how tube fill lines determine collection volume, and which packing and temperature instructions come from your laboratory.
Evidence-based breakdown of the training periodization, recovery protocols, and nutrition strategies elite UFC fighters use in 2025, including blood flow restriction, cold water immersion, and weight-cut reform.
Evidence-based guide to deciding whether a weight loss coach fits your goals, what the research says about behavioral coaching outcomes, and how to evaluate credentials.
A practical, evidence-based look at creatine monohydrate: who it clearly helps, who needs a doctor's input first, and where the research is still thin. Pending qualified medical review.
Immunosenescence can outpace biological age by decades. Learn the biomarkers that reveal immune aging, plus evidence-based strategies to rebuild immune resilience.
Alendronate lowers bone turnover. In the FLEX trial, bone-specific ALP was 28.1% higher after switching to placebo than after continuing treatment.
How oral estradiol affects ALT levels, including direction of change, magnitude, time course, mechanism, and when to monitor liver enzymes during menopausal hormone therapy.
Oral estradiol changes HDL, LDL, and triglyceride levels through hepatic first-pass metabolism. Learn the direction, magnitude, timing, and monitoring schedule backed by RCT data.
Estradiol transdermal patches have measurable but generally modest effects on CMP markers including liver enzymes, fasting glucose, electrolytes, and kidney function. Here is what clinicians monitor and why.
Transdermal estradiol changes total cholesterol, LDL, HDL, and triglycerides differently than oral estrogen. Learn the direction, magnitude, timing, and monitoring schedule backed by clinical trial data.